Ontology highlight
ABSTRACT: Background
The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib.Method
A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression.Results
One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11.42 (95% confidence interval [CI], 9.7-15.9) and 15.8 months (95% CI, 13.9-25.7). PFS by Choi (Kendall's τ = 0.72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0.43). RECIST incorrectly estimated prognosis in 49.6%. Partial response rate increased from 12.8% to 47.4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival.Conclusion
Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
SUBMITTER: Solis-Hernandez MP
PROVIDER: S-EPMC6889276 | biostudies-literature | 2019 Oct
REPOSITORIES: biostudies-literature
Solis-Hernandez Mª Pilar MP Fernandez Del Valle Ana A Carmona-Bayonas Alberto A Garcia-Carbonero Rocio R Custodio Ana A Benavent Marta M Alonso Gordoa Teresa T Nuñez-Valdovino Bárbara B Sanchez Canovas Manuel M Matos Ignacio I Alonso Vicente V Lopez Carlos C Viudez Antonio A Izquierdo Marta M Calvo-Temprano David D Grande Enrique E Capdevila Jaume J Jimenez-Fonseca Paula P
British journal of cancer 20190903 7
<h4>Background</h4>The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib.<h4>Method</h4>A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression.<h4>Results</h4>One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11. ...[more]